Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, is pleased to announce that it has signed a deal with Cobra Biomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice (`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence clinical trials of SCIB1 in the UK in 1Q2010.
Scancell is developing SCIB1, a DNA vaccine for the potential treatment of late-stage melanoma cancer patients. There are 8000 new cases of melanoma every year in the UK with 1800 deaths per year. Early stage melanoma is often cured by surgery but advanced disease has a very poor prognosis with late stage (stage IV) disease having a median survival of approximately 6 months. SCIB1 was developed using Scancell's ImmunoBody(tm) technology and is engineered to express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In animal models, SCIB1 prevented the development of lung metastases and significantly inhibited the growth of established tumours.
Cobra Biomanufacturing is an AIM-listed contract manufacturer of biopharmaceuticals that is compliant with cGMP standards worldwide.
David Evans, chairman of Scancell, commented:
"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our SCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule is testament to the progress the Company continues to achieve." Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
"We are very pleased to be have been selected by Scancell as a result of Cobra's abilities and reputation as a leading cGMP compliant manufacturer of DNA. This agreement also underscores Cobra's long term commitment to the manufacture of therapeutic vaccines."
The Directors of the issuer accept responsibility for this announcement.
The patent protects a new class of cancer vaccines rolling off the Moditope platform
Wed, 23 May 2018 05:28:00
Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.
A placing and subscription at 12 pence a share will account for £6mln of the total.
The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.
Wed, 18 Apr 2018 12:18:00
In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline
Wed, 18 Apr 2018 13:15:00